DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL)
Recalled by SUN PHARMACEUTICAL INDUSTRIES INC
Class I — most serious
There is a reasonable chance that using this product could cause serious health problems or death.
SUN PHARMACEUTICAL INDUSTRIES INC has recalled DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on June 17, 2026 and was initiated on May 12, 2026. It is classified as a Class I recall, which means there is a reasonable chance that using this product could cause serious health problems or death.
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), with approximately 675 vials affected. The company behind the recall is SUN PHARMACEUTICAL INDUSTRIES INC, based in Princeton, NJ. The FDA describes the product as: “DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), 25 mL single-dose vials, Sterile, Rx only, Manufactured for: Northstar Rx LLC., Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol, Gujarat, India, ND…”
Why was DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL) recalled?
According to the FDA, the stated reason for the recall is: “Presence of Particulate matter: Particulate matter identified as glass.” In plain terms, this recall relates to foreign material.
A foreign material recall means that pieces of something which should not be in food — such as metal, plastic, or glass — may be present. These can pose a choking hazard or cause injury. Recalls like these are issued to remove the affected product before anyone is hurt.
What should you do?
If you think you may have bought DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL), compare it against the product description and identifying codes (Lot HAG2581B, expires: 05/31/2027) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact SUN PHARMACEUTICAL INDUSTRIES INC or your local health authority.
About this recall
This recall was distributed in NJ. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Who this recall affects
This recall matters to anyone who bought DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL). Even if you feel fine, it's worth checking what you have on hand rather than assuming you were missed.
Distribution listed in the notice: U.S. Nationwide.
What foreign material actually means
A foreign material recall means that pieces of something which should not be in food — such as metal, plastic, or glass — may be present. These can pose a choking hazard or cause injury. Recalls like these are issued to remove the affected product before anyone is hurt.
In this case, the concern applies specifically to DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL) from SUN PHARMACEUTICAL INDUSTRIES INC — not to the wider category of products. Similar items from other brands aren't part of this recall.
How to check whether you have it
On medicine bottles, the lot number and expiration date are printed on the pharmacy label or stamped directly on the manufacturer's bottle — often near the bottom edge or on the back. If a pharmacy label covers it, your pharmacist can look up the lot they dispensed.
Compare what you find against the identifying details in this recall: Lot HAG2581B, expires: 05/31/2027
What to do if you already bought it
Do not stop taking a prescribed medicine on your own because of a recall — for many conditions, an interrupted dose carries its own risk.
Instead, check the lot number against the details above and contact your pharmacist, who can confirm what they dispensed and arrange a replacement.
If you've had an unexpected reaction, contact your healthcare provider. Problems can also be reported to the FDA's MedWatch program.
Full recall details
- Status
- Ongoing
- Date reported
- June 17, 2026
- Recall started
- May 12, 2026
- Distributed in
- NJ
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL) recalled?+
According to the FDA: Presence of Particulate matter: Particulate matter identified as glass.
How serious is this recall?+
Class I — most serious. There is a reasonable chance that using this product could cause serious health problems or death.
What should I do if I have DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mL (2mg/mL)?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0580-2026. Information last synced from the FDA on August 21, 2026.
